Contineum Therapeutics (CTNM) News Today $4.62 +0.24 (+5.48%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$4.60 -0.02 (-0.43%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Head to Head Survey: Contineum Therapeutics (CTNM) & Its PeersApril 15, 2025 | americanbankingnews.comNorges Bank Acquires Shares of 169,729 Contineum Therapeutics, Inc. (NASDAQ:CTNM)Norges Bank bought a new stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 169,729 shares of the company's stock, valued at approximately $2,487,000. NoApril 14, 2025 | marketbeat.comContineum Therapeutics Rings the Nasdaq Stock Market Closing BellApril 10, 2025 | nasdaq.comContineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Consensus PT from BrokeragesApril 10, 2025 | americanbankingnews.comContineum Therapeutics Rings the Closing BellApril 10, 2025 | nasdaq.comADAR1 Capital Management LLC Raises Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM)ADAR1 Capital Management LLC boosted its stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 817.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,234 shares of the companyApril 9, 2025 | marketbeat.comContineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Recommendation of "Buy" by BrokeragesShares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) have been given a consensus rating of "Buy" by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buApril 8, 2025 | marketbeat.comContineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of DirectorsMarch 17, 2025 | finance.yahoo.comContineum Therapeutics Appoints Diego Miralles to BoardMarch 17, 2025 | tipranks.comContineum initiated with a Buy at JonesResearchMarch 15, 2025 | markets.businessinsider.comContineum Therapeutics (NASDAQ:CTNM) Now Covered by Jones TradingJones Trading started coverage on shares of Contineum Therapeutics in a research note on Thursday. They issued a "buy" rating and a $23.00 price objective for the company.March 14, 2025 | marketbeat.comJones Trading Initiates Coverage of Contineum Therapeutics (CTNM) with Buy RecommendationMarch 14, 2025 | msn.comInstitutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%March 13, 2025 | finance.yahoo.comContineum Therapeutics to Present at the Stifel 2025 Virtual CNS ForumMarch 12, 2025 | businesswire.comMorgan Stanley Reiterates "Overweight" Rating for Contineum Therapeutics (NASDAQ:CTNM)Morgan Stanley restated an "overweight" rating and set a $25.00 price objective on shares of Contineum Therapeutics in a research report on Friday.March 8, 2025 | marketbeat.comRobert W. Baird Issues Pessimistic Forecast for Contineum Therapeutics (NASDAQ:CTNM) Stock PriceRobert W. Baird reduced their price target on shares of Contineum Therapeutics from $32.00 to $16.00 and set an "outperform" rating on the stock in a report on Friday.March 8, 2025 | marketbeat.comContineum assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comContineum price target lowered to $16 from $32 at BairdMarch 7, 2025 | markets.businessinsider.comContineum reports Q4 EPS (56c), consensus (44c)March 6, 2025 | markets.businessinsider.comContineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development MilestonesMarch 6, 2025 | businesswire.comContineum initiates dosing in phase 1b Chronic Pain trial of PIPE-791March 4, 2025 | markets.businessinsider.comContineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791March 4, 2025 | finance.yahoo.comContineum Therapeutics (CTNM) Expected to Announce Quarterly Earnings on WednesdayContineum Therapeutics (NASDAQ:CTNM) will be releasing earnings before the market opens on Wednesday, February 26, Financial Modeling Prep reports.February 21, 2025 | marketbeat.comContineum Therapeutics, Inc. Class A Common Stock (CTNM) Institutional HoldingsFebruary 19, 2025 | nasdaq.comContineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest UpdateContineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 869,400 shares, a decrease of 7.0% from the January 15th total of 934,400 shares. Based on an average trading volume of 92,900 shares, the days-to-cover ratio is presently 9.4 days. Approximately 6.2% of the shares of the company are sold short.February 18, 2025 | marketbeat.comContineum Therapeutics (CTNM) Projected to Post Earnings on WednesdayContineum Therapeutics (NASDAQ:CTNM) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.January 29, 2025 | marketbeat.comContineum Therapeutics' (CTNM) Outperform Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and set a $31.00 price target on shares of Contineum Therapeutics in a report on Thursday.January 9, 2025 | marketbeat.comContineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)January 8, 2025 | businesswire.comFranklin Resources Inc. Buys 820,542 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)Franklin Resources Inc. raised its stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 130.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,447,550 shares of the company's stock aftDecember 19, 2024 | marketbeat.comContineum initiates patient dosing in Phase 1B PET trialDecember 18, 2024 | markets.businessinsider.comContineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791December 16, 2024 | finance.yahoo.comContineum Therapeutics Inc Class A Common StockDecember 11, 2024 | morningstar.comFmr LLC Buys 373,327 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)Fmr LLC grew its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 115.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 696,927 shares of the company's stock after acquiring an aDecember 11, 2024 | marketbeat.comSuvretta Capital Management LLC Sells 333,334 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)Suvretta Capital Management LLC reduced its position in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 16.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,720,000 shares of the company's stock after selling 333,334 shares during the period. SuvrNovember 29, 2024 | marketbeat.comContineum Therapeutics, Inc. (CTNM)November 28, 2024 | finance.yahoo.comContineum Therapeutics: Q3 2024 Financial OverviewNovember 25, 2024 | tipranks.comContineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceNovember 25, 2024 | finance.yahoo.comContineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceNovember 25, 2024 | businesswire.comContineum announces FDA authorization for PIPE-791November 19, 2024 | markets.businessinsider.comContineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic PainNovember 19, 2024 | businesswire.comHere's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn SituationNovember 14, 2024 | finance.yahoo.comContineum Therapeutics to Attend Upcoming Investor ConferencesNovember 13, 2024 | businesswire.comContineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from Stifel NicolausNovember 9, 2024 | markets.businessinsider.comContineum Therapeutics (NASDAQ:CTNM) Issues Quarterly Earnings ResultsContineum Therapeutics (NASDAQ:CTNM - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.01.November 9, 2024 | marketbeat.comRoyal Bank of Canada Cuts Contineum Therapeutics (NASDAQ:CTNM) Price Target to $31.00Royal Bank of Canada reduced their target price on Contineum Therapeutics from $32.00 to $31.00 and set an "outperform" rating for the company in a research note on Thursday.November 7, 2024 | marketbeat.comContineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 6, 2024 | businesswire.comContineum initiated with an Outperform at BairdOctober 23, 2024 | markets.businessinsider.comPromising Prospects and Strong Financials Bolster Buy Rating for Contineum TherapeuticsOctober 23, 2024 | markets.businessinsider.comContineum Therapeutics (NASDAQ:CTNM) Rating Increased to Strong-Buy at Baird R WBaird R W upgraded shares of Contineum Therapeutics to a "strong-buy" rating in a research note on Tuesday.October 23, 2024 | marketbeat.comBaird Initiates Coverage of Contineum Therapeutics (CTNM) with Outperform RecommendationOctober 22, 2024 | msn.com Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address CTNM Media Mentions By Week CTNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTNM News Sentiment▼0.430.53▲Average Medical News Sentiment CTNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTNM Articles This Week▼21▲CTNM Articles Average Week Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PGEN News Today MNMD News Today STOK News Today UPB News Today PRTC News Today SANA News Today SION News Today RVNC News Today ABVX News Today ZVRA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTNM) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTNM Stock Free CTNM Stock Alerts